Etelae-Savon hyvinvointialue
- Address
- lock Available on a paid plan
Neoplasms and Cancer Care
At Etelae-Savon hyvinvointialue in Mikkeli, clinical research is focused on neoplasms, with studies centered on cancer and advanced colorectal cancer. The work reflects a strong oncology profile within the hospital setting, with trials aimed at understanding disease behavior and supporting better treatment decisions.
- Research on metastatic or locally advanced inoperable colorectal cancer, examining how the disease develops and how well it can be surgically managed.
- Studies assessing the safety and continued use of darolutamide for people who have already received treatment in another study.
- Clinical focus on improving treatment effectiveness, patient outcomes, and long-term disease control in oncology care.
The trials at this site combine cancer treatment evaluation with real-world clinical insight, helping researchers better understand both ongoing therapy safety and the practical outcomes of advanced disease management.
Colorectal Cancer Research
This research area concentrates on metastatic colorectal cancer, with attention to how the disease behaves in patients across Finland and how often surgery may still be possible. The studies are designed to improve knowledge of resectability, postoperative recovery, and survival patterns in a challenging form of gastrointestinal cancer.
- Population-based research into the clinical course of metastatic colorectal cancer.
- Evaluation of resectability and postoperative morbidity after surgery.
- Work aimed at refining prognosis and guiding more effective cancer care.
The RAXO trial highlights the site’s contribution to understanding advanced colorectal disease and supporting better planning of treatment strategies for patients with complex oncology needs.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1HUS-yhtymae1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 107 other sites in Finland
Therapeutic Area Benchmark — Finland
Select a therapeutic area to compare against other sites in Finland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Finland
Market Share
Country: Finland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Etelae-Savon hyvinvointialue
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (20321) An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer sponsored studies | Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2020 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Capecitabine | 1 | Unknown | 2025-01-25 | 2025-01-25 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.